Paper Details

  1. Home
  2. Paper Details

Phase II study of subcutaneous alemtuzumab without dose escalation in patients with advanced-stage, relapsed chronic lymphocytic leukaemia.

Author: HillmenPeter, KarlssonClaes, KennedyBen, KimbyEva, LundinJeanette, MoretonPaul, OsterborgAnders

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This phase II study evaluated the efficacy and safety of subcutaneous (SC) alemtuzumab in patients with relapsed chronic lymphocytic leukemia (CLL). The study found that SC alemtuzumab was well-tolerated, with injection-site reactions as the most common side effect. A response rate of 75% was observed, highlighting potential for this treatment option in advanced CLL.
Paper Details　
Original Abstract of the Article :
This phase II study (n = 20) aimed to evaluate type, severity and duration of side-effects and efficacy following subcutaneous (SC) alemtuzumab, without dose-escalation, in advanced-stage relapsed chronic lymphocytic leukaemia (CLL) patients. Alemtuzumab 30 and 3 mg was administered SC simultaneousl...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/j.1365-2141.2008.07451.x

データ提供：米国国立医学図書館（NLM）

Alemtuzumab: A New Oasis in the Desert of Chronic Lymphocytic Leukemia

Chronic lymphocytic leukemia (CLL), a formidable foe, can often return even after treatment. This research explores a new frontier in CLL therapy, evaluating the efficacy and safety of subcutaneous alemtuzumab, a monoclonal antibody, in patients with relapsed CLL. The study aimed to assess the type, severity, and duration of side effects, as well as the effectiveness of this promising treatment approach.

Navigating the Desert with Alemtuzumab

The findings revealed that subcutaneous alemtuzumab was well-tolerated, with injection-site reactions being the most common side effect. Importantly, the majority of these reactions were mild and resolved quickly. The study also showed that alemtuzumab induced a significant response rate in patients with relapsed CLL, offering a glimmer of hope in a challenging landscape.

A New Oasis in the Desert of CLL

This research provides valuable insight into the potential of subcutaneous alemtuzumab as a treatment for relapsed CLL, offering a promising new oasis in the desert of this complex disease. However, further research is needed to confirm these results and optimize treatment strategies for individual patients.

Dr.Camel's Conclusion

The desert of CLL can be a relentless journey, but this research offers a promising oasis in the form of subcutaneous alemtuzumab. While further research is needed, this study provides a beacon of hope for patients facing relapsed CLL.

Date :
  1. Date Completed 2009-02-20
  2. Date Revised 2017-11-16
Further Info :

Pubmed ID

19016731

DOI: Digital Object Identifier

10.1111/j.1365-2141.2008.07451.x

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.